Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Vienna - Delayed Quote EUR

Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)

52.75
+1.30
+(2.53%)
At close: 3:30:30 PM GMT+2
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for REC.VI

Recent News: REC.VI

View More
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION
GlobeNewswire 4 days ago
3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%

3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%
Simply Wall St. 15 days ago
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME
GlobeNewswire 16 days ago
3 European Stocks Estimated To Be Undervalued In March 2025

3 European Stocks Estimated To Be Undervalued In March 2025
Simply Wall St. last month
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS
GlobeNewswire 2 months ago
3 Companies That May Be Trading Below Their Estimated Value

3 Companies That May Be Trading Below Their Estimated Value
Simply Wall St. 3 months ago

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com 5 months ago
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%
GlobeNewswire 5 months ago

Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com 6 months ago
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati

Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Benzinga 6 months ago
Sanofi’s rare disease drug finds yet another home

Sanofi’s rare disease drug finds yet another home
BioPharma Dive 6 months ago
View More

Related Tickers

BAYA.BE Bayer AG
6.00
+3.45%
 
4519N.MX Chugai Pharmaceutical Co., Ltd.
1,121.87
0.00%
 
AMGN.MX Amgen Inc.
5,510.00
0.00%
 
MRK.BA Merck & Co., Inc.
20,325.00
+0.62%
 
MRK.MX Merck & Co., Inc.
1,637.00
-1.50%
 
SNW2.MU Sanofi SA
48.00
+1.27%
 
NOV.MU Novo Nordisk A/S
60.94
+3.83%
 
COPNz.XC
 
4AB.F AbbVie Inc.
170.20
-0.47%
 
NOVA.F Novo Nordisk A/S
60.80
+4.47%